Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Jul 29;5(9):e1216292.
doi: 10.1080/2162402X.2016.1216292. eCollection 2016.

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Luca Antonioli  1 , Corrado Blandizzi  2 , Fabio Malavasi  3 , Davide Ferrari  4 , György Haskó  5
Affiliations
Editorial

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Luca Antonioli et al. Oncoimmunology. .

Abstract

The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.

Keywords: CD73; autophagy; immunotherapy; monoclonal antibody; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Scheme showing the role played by CD73 in the tumor microenvironment. CD73-derived adenosine shapes the cancer milieu, leading to the generation of a marked immunosuppressive and pro-angiogenic environment that paves the way to neoplasia development. ATP: adenosine triphosphate; AMP: adenosine monophosphate; DC: dendritic cell; MSDC: myeloid-derived suppressor cells; NK cell: natural killer cell; Treg cell: regulatory T cell. ↑: increases; ↓: decreases.
See this image and copyright information in PMC

References

    1. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13:842-57; PMID:24226193; http://dx.doi.org/10.1038/nrc3613 - DOI - PubMed
    1. Tsai MJ, Chang WA, Huang MS, Kuo PL. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem 2014; 2014:351959; PMID:25937967; http://dx.doi.org/10.1155/2014/351959 - DOI - PMC - PubMed
    1. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57:2602-5; PMID:9205063 - PubMed
    1. Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2016; 2:95-109; PMID:27014745; http://dx.doi.org/10.1016/j.trecan.2016.01.003 - DOI - PMC - PubMed
    1. Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy 2016; 8:145-63; PMID:26808918; http://dx.doi.org/10.2217/imt.15.106 - DOI - PubMed

Publication types